Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 7/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 8/20 | 0.53 |
| ▸ | CA2 | P00918 | 8/20 | 0.53 |
| ▸ | CA9 | Q16790 | 8/20 | 0.53 |
| ▸ | CA12 | O43570 | 7/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27719976 | 1.00 | PYGB (0.56) | PYGBGAACA1CA2CA9 | |
| SCHEMBL7121127 | 1.00 | PYGB (0.56) | PYGBGAACA1CA2CA9 | |
| SCHEMBL29936756 | 1.00 | PYGB (0.56) | PYGBGAACA1CA2CA9 | |
| SCHEMBL31259342 | 1.00 | PYGB (0.56) | PYGBGAACA1CA2CA9 | |
| SCHEMBL30802065 | 1.00 | PYGB (0.56) | PYGBGAACA1CA2CA9 | |
| SCHEMBL1520710 | 1.00 | PYGB (0.56) | PYGBGAACA1CA2CA9 | |
| SCHEMBL8651363 | 1.00 | PYGB (0.56) | PYGBGAACA1CA2CA9 | |
| SCHEMBL1520707 | 1.00 | PYGB (0.56) | PYGBGAACA1CA2CA9 | |
| SCHEMBL7125701 | 1.00 | PYGB (0.56) | PYGBGAACA1CA2CA9 | |
| SCHEMBL11416148 | 0.85 | PYGB (0.59) | PYGBGAACA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716493-B2 | Multicyclic compounds and the use thereof | CEPHALON, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| EP-2066324-B1 | CYCLOALKANOPYROLOCARBAZOLE DERIVATIVES AND THE USE THEREOF AS PARP, VEGFR2 AND MLK3 INHIBITORS | CEPHALON INC (US) | 2013-05-29 | — | — | EP | disclosed |
| US-20110059959-A1 | NOVEL MULTICYCLIC COMPOUNDS AND THE USE THEREOF | CEPHALON, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| EP-2050750-B1 | Multicyclic compounds and their use as inhibitors of PARP, VEGFR2 and MLK3 enzymes | CEPHALON INC (US) | 2010-09-22 | — | — | EP | disclosed |
| EP-2066324-A2 | CYCLOALKANOPYROLOCARBAZOLE DERIVATIVES AND THE USE THEREOF AS PARP, VEGFR2 AND MLK3 INHIBITORS | CEPHALON, INC. (US) | 2009-06-10 | — | — | EP | disclosed |
| EP-2050750-A2 | Multicyclic compounds and their use as inhibitors of PARP, VEGFR2 and MLK3 enzymes | CEPHALON, INC. (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2007149451-A2 | CYCLOALKANOPYRROLOCARBAZOLE DERIVATIVES AND THE USE THEREOF AS PARP, VEGFR2 AND MLK3 INHIBITORS | CEPHALON, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
| EP-1754707-A2 | Multicyclic compounds and their use as inhibitors of PARP, VEGFR2 and MLK3 enzymes | CEPHALON, INC. (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060276497-A1 | Novel multicyclic compounds and the use thereof | CEPHALON, INC. (US) | 2006-12-07 | — | — | US | disclosed |
| US-7122679-B2 | Multicyclic compounds and the use thereof | CEPHALON, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1294725-B1 | MULTICYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PARP, VEGFR2 AND MLK3 ENZYMES | CEPHALON INC (US) | 2006-01-04 | — | — | EP | disclosed |
| EP-1294725-A2 | MULTICYCLIC COMPOUNDS AND THE USE THEREOF AS INHIBITORS OF PARP, VEGFR2 AND MLK3 ENZYMES | CEPHALON, INC. (US) | 2003-03-26 | — | — | EP | disclosed |
| US-20020028815-A1 | Novel multicyclic compounds and the use thereof | CEPHALON, INC. | 2002-03-07 | — | — | US | disclosed |
| WO-2001085686-A2 | MULTICYCLIC COMPOUNDS AND THE USE AS INHIBITORS OF PARP, VEGFR2 AND MLK3 ENZYMES | CEPHALON, INC. (US) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276497-A1 | Novel multicyclic compounds and the use thereof | MLKL, PARP3, PARP1 | PYGB 124/4885GAA 1180/4885CA1 3731/4885 |
| US-20020028815-A1 | Novel multicyclic compounds and the use thereof | MLKL, PARP3, PARP1 | PYGB 124/4885GAA 1180/4885CA1 3731/4885 |
| US-20110059959-A1 | NOVEL MULTICYCLIC COMPOUNDS AND THE USE THEREOF | MLKL, PARP3, PARP1 | PYGB 124/4885GAA 1180/4885CA1 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.